M6620 Plus Standard Treatment in Oesophageal and Other Cancer
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This Phase I study will test the combination of a novel ATR inhibitor (M6620) with
chemoradiotherapy in oesophageal cancer; utilizing three experimental cohorts (Stage A1, A2
and B).